News

18.09.2017

13 startup projects qualify for the first phase of BaseLaunch

13 startup projects qualify for the first phase of BaseLaunch

The BaseLaunch Healthcare Accelerator program from BaselArea.swiss started on September 14. Over 100 applications were received from more than 30 countries, and the selection committee has selected 13 projects to go on to Phase I. Now, the project teams will work with industry experts to further develop their business case over the next three months.

mehr >
19.09.2017

Keith A. Katkin named CEO of Urovant

Keith A. Katkin named CEO of Urovant

The Basel-based pharmaceutical company Urovant has appointed Keith A. Katkin as its new CEO. With extensive experience in the pharmaceutical industry, he aims to advance the development of the lead candidate vibegron, which was developed to treat overactive bladder.

mehr >
14.09.2017

Patient Data – Faster but with Respect and Trust

The panel (starting from left): Effy Vayena, ETH Zurich; Marcel Tanner, Swiss TPH, Switzerland Torsten Schwede, University of Basel and SIB; Paul Wicks, PatientsLikeMe; Susanne Baars, Human Genome Foundation; Thomas Bachofner, Swisscom Heatlh; Frank Baiden, Institute of Public Health, Ghana

“Faster but with Respect and Trust“ - these were the final words from Effy Vayena at the DayOne Experts event at EMBO Basel life.  The message was to encourage the healthcare and life science communities to move faster to make the large scale use of patient data a reality whilst dealing with this data with enough respect for the individual to deserve the trust the patient has in the system. 

mehr >
05.09.2017

"In Switzerland, we often sell promising technologies too early"

Ulf Claesson is a "serial entrepreneur". During the past 25 years, he has set up companies that have gone on to become firmly established in the market. In 2012, he joined Clinerion as CEO and shareholder. Since then, the company has positioned itself in the medical data field and recently entered into a partnership with British company Cisiv. Clinerion's software helps recruit patients for clinical trials run by major pharmaceutical companies – in real time. But the competition never sleeps. A growing number of competitors is now appearing, especially in the USA where there is no shortage of risk capital. In this interview for the Innovation Report, Claesson explains how the Basel-based healthtech company plans to maintain its leadership position.

mehr >
14.09.2017

Genedata simplifies cell analysis

Basel – The Basel-based company Genedata has launched a new solution based on artificial learning to facilitate the identification of substances that can alter a cell’s phenotype.

mehr >
13.09.2017

BC Platforms launches analytics tool

BC Platforms launches analytics tool

The Basel-based data management company BC Platforms has launched BC|RQUEST, a resource for the integrated analysis of genomic and clinical data.

mehr >
04.07.2017

"I want to turn innovative research into new drugs"

Cellestia CEO Michael Bauer.

Each year some 250,000 patients develop a type of cancer because of faulty communication between cells. This malfunction occurs in what is known as the NOTCH signal path. There are currently no effective treatments – but this is set to change. Cellestia Biotech AG is developing an innovative drug against this type of cancer by using a novel active ingredient that selectively attacks the malfunctioning cell communication. The drug could be used to treat leukaemia, lymphomas and solid tumours such as breast cancer.

mehr >
12.09.2017

Ascensia Diabetes Care simplifies insulin management

The Basel-based company Ascensia Diabetes Care is collaborating with the Finnish company Quattro Folia to connect Ascensia’s blood glucose monitoring system with Quattro Folia’s app.

mehr >
11.09.2017

Evolva awarded contract from U.S. government

Evolva awarded contract from U.S. government

The ingredient manufacturer Evolva has been awarded a contract by the U.S. government to develop a new form of protection against insects in an effort to combat mosquito-borne diseases like Zika.

mehr >
13.06.2017

Roivant is creating a buzz in Basel

Roivant is creating a buzz in Basel

Roivant Sciences, a fast-growing life sciences company from the US, recently opened its global headquarters in Basel. In celebration of their newly established location, Roivant, together with BaselArea.swiss, invited stakeholders from the life sciences sector to “Halle 7, Gundeldingerfeld” in Basel on June 8th 2017 for a panel discussion on the future of healthcare.

mehr >
08.09.2017

BaseLaunch Accelerator gains another healthcare partner

Pharma and diagnostics company Roche has joined Johnson & Johnson Innovation, Novartis Venture Fund and Pfizer to become the fourth healthcare partner on the committee of the BaselArea.swiss accelerator program for healthcare startups.

mehr >
07.09.2017

Michael N. Hall receives Lasker Award

Michael N. Hall receives Lasker Award

Michael N. Hall from the University of Basel’s Biozentrum is the sole recipient of this year’s Lasker Basic Medical Research Award. The biochemist received the honour for his research on regulating cell growth.

mehr >
08.06.2017

BaselArea.swiss got off to a successful start

BaselArea.swiss got off to a successful start

In its first annual report, the newly formed BaselArea.swiss can look back on a successful 2016. The joint initiative for innovation and economic promotion by the cantons of Basel-Stadt, Basel-Landschaft and Jura succeeded in growing in all areas. It provided assistance to 36 companies moving to the region, which corresponds to a 50% increase over the previous year. In the area of innovation promotion, over 4,000 participants attended 80 events, expanding the regional network from 8,000 to 13,000 innovators and experts. The services provided by BaselArea.swiss were also actively used to promote start-up projects, contributing to 43 companies being founded.

mehr >
05.09.2017

Halozyme Therapeutics opens European headquarters

Halozyme Therapeutics opens European headquarters

Halozyme, a U.S. biotechnology company developing novel oncology and drug-delivery therapies, has established their European headquarters office in Basel, Switzerland.

mehr >
05.09.2017

Der erste BaselHack: Schnell und kreativ

Der erste BaselHack: Schnell und kreativ

Als Stefani Gerber gefragt wurde, ob sie beim ersten BaselHack mithelfen wolle, zögerte die Softwareentwicklerin nicht. «Der BaselHack entstand aus der Idee, etwas für die Community in Basel anzubieten», sagt sie. Denn am Rhein wächst die IT-Branche dank der Ausbildungen an FHNW, Universität Basel, Berufsschulen und Nachwuchsförderung. Zudem gibt es viele interessante Arbeitsplätze im IT-Sektor. Man treffe sich regelmässig zu Branchen-Meetups, so Gerber. Kurzerhand wurde ein Verein BaselHack gegründet; 20 Leute engagieren sich freiwillig.

mehr >
08.06.2017

A molecular assembly line to cure the body

A molecular assembly line to cure the body

Imagine that certain forms of blindness could be cured. Or imagine that the body itself could produce a cure for some of its own diseases. These may be just some of the results of the National Centre of Competence in Research Molecular Systems Engineering (NCCR MSE). Its long-term goals are to create molecular systems and factories for the production of high added-value chemicals and develop cellular systems for new applications in medical diagnostics, therapy and treatment. Director Thomas Ward is aiming high: He wants to make Basel the leading hub for the next European flagship project. At stake: one billion euro.

mehr >
05.09.2017

The Congress “Basel Life” combines science and business

The Congress “Basel Life” combines science and business

“Basel Life will take place from 10th to 13th September 2017 in the Congress Center Basel and combines basic research and translational research with science and business. Throughout the four days the congress will be offering a knowledge transfer at the highest international level. Among the main speakers will be Jennifer Doudna, UC Berkeley, USA, und Svante Pääbo, MPI for Evolutionary Anthropology, DE, as well as many other excellent speakers.

mehr >
05.09.2017

La réalité augmentée dans le monde industriel

La réalité augmentée dans le monde industriel

Pour le tout public, la réalité augmentée ressemble plutôt à une personne portant de grosses lunettes semblables à celles que nous utilisons pour le ski, accrochée à une console de jeux. Le sujet est justement bien connu dans le secteur des jeux vidéos et nous en entendons également parler dans les domaines de l’éducation par le jeu, le cinéma ou la télévision. Ainsi certaines applications vous permettent par exemple de transformer votre tablette en «scanner» pour apprendre à reconnaître et nommer les différents os du squelette humain.

mehr >
15.05.2017

Investing in strengths – Swiss leadership in life sciences

Investing in strengths – Swiss leadership in life sciences

How can Switzerland and the Basel region maintain their international leadership role in life sciences? As part of the Biotech and Digitization Day, Federal Councillor Johann Schneider-Ammann visited the Basel region to discuss current trends and challenges with a high-ranking delegation from politics, business, research and start-ups.

mehr >
04.09.2017

«Medtech & Pharma Platform» erneut in Basel

«Medtech & Pharma Platform» erneut in Basel

Die vierte Ausgabe des internationalen Kongresses «Medtech & Pharma Platform» findet zwischen dem 26. und 27. Oktober 2017 im Congress Center Basel statt.

mehr >
04.09.2017

Vas Narasimhan to take over as Novartis CEO

Vas Narasimhan to take over as Novartis CEO

Vas Narasimhan will be responsible for steering the future of Novartis when he takes over as CEO on 1 February 2018. The successor of Joseph Jimenez is currently Global Head of Drug Development and Chief Medical Officer at the pharmaceutical company.

mehr >
09.05.2017

The healthcare system must take responsibility

The healthcare system must take responsibility

Kristian Schneider wants to improve the quality of health care and better manage the rising healthcare costs by means of a network that includes doctors, hospitals, insurance companies and the state. Its aim is to provide exactly those services needed for the health of patients. For the canton of Jura, which like all other cantons suffers from the fragmentation of service providers, this could be a unique opportunity to build an integrative care system – and thus become a pioneer, says the director of Hôpital du Jura.

mehr >
31.08.2017

Novartis gets green light for gene therapy

Novartis gets green light for gene therapy

The U.S. Food and Drug Administration FDA has approved Kymriah, a therapy developed by the Basel-based pharmaceutical giant Novartis to treat a type of leukemia. It is the first gene therapy to be approved in the USA.

mehr >
30.08.2017

Basel pharmacy integrates innovative mini-clinic

Basel pharmacy integrates innovative mini-clinic

Patients at a TopPharm pharmacy in Basel can soon receive outpatient services by means of video consultation. The solution is provided by Medgate, which wants to expand across Switzerland with its modern Mini Clinics.

mehr >
21.04.2017

Basel-Landschaft welcomes new companies

Basel-Landschaft welcomes new companies

The canton of Basel-Landschaft welcomed a host of new companies over the past few weeks. BaselArea.swiss played in a big role in attracting the companies to establish themselves in Basel.

mehr >
30.08.2017

Basel-Landschaft companies will continue to benefit from CSEM

Liestal – The Basel-Landschaft government will continue to support the regional centre of the Swiss Center for Electronics and Microtechnology (CSEM) in Muttenz. The centre is a catalyst for innovation, helping SMEs in the region in particular.

mehr >
29.08.2017

Novartis names Bertrand Bodson Chief Digital Officer

Novartis names Bertrand Bodson Chief Digital Officer

The Basel-based pharmaceutical company Novartis has appointed Bertrand Bodson to the new role of Chief Digital Officer. Bodson will be responsible for creating and executing a company-wide digital strategy.

mehr >
12.04.2017

“I see a very innovation-friendly climate in Basel”

“I see a very innovation-friendly climate in Basel”

It all began with research resources that were a quarter of a century old. Simon Ittig and his colleagues at the Biozentrum of the University of Basel turned these into a research project – and eventually a start-up. T3 Pharmaceuticals develops new therapies to treat solid tumours.

mehr >
28.08.2017

Aurealis Pharma AG raises 5.6 million Swiss francs

Aurealis Pharma AG raises 5.6 million Swiss francs

Aurealis Pharma AG has closed a 5.6 million Swiss franc financing round. Headquartered in Basel and Finland, the biotechnology company develops medications for cancer and chronic inflammation.

mehr >
24.08.2017

3D im Spital

3D im Spital

Wo der 3D-Druck bereits heute standardmässig eingesetzt wird, in welche Richtungen sich die Technik entwickelt und welche rechtlichen Fragen dadurch auftauchen, zeigte das Symposium «3D Printing for Life Sciences» an der Hochschule für Life Sciences in Muttenz auf. BaselArea.swiss führte die Veranstaltung mit Unterstützung des Universitätsspitals Basel und des Kantonsspitals Baselland durch. Falko Schlottig, Direktor der Hochschule für Life Sciences, und Sébastien Meunier von BaselArea.swiss begrüssten über 200 Teilnehmerinnen und Teilnehmer in der Aula.

mehr >
05.04.2017

Companies continue to find Switzerland appealing

View over the Rhine river

Bern – More foreign companies relocated to Switzerland last year than in any previous year. Economic development agencies attracted innovative companies with high value creation.

mehr >
24.08.2017

Infors AG opens up Big Data use

Infors AG opens up Big Data use

The laboratory supplier Infors AG has developed a software that facilitates the analysis of large volumes of data within the pharma and biotechnology sectors. eve meets European and American regulatory requirements.

mehr >
22.08.2017

Novartis uses smartphone for MS study

Novartis uses smartphone for MS study

The Basel-based pharmaceutical company Novartis has launched a large-scale research study on multiple sclerosis (MS) that allows participants to contribute by sending data via their smartphones.

mehr >
20.03.2017

Swiss are among the happiest people in the world

Swiss are among the happiest people in the world

Switzerland is one of the four happiest countries in the world, according to the latest World Happiness Report. The study looks at GDP per capita, trust in government and business, and other social factors relating to well-being.

mehr >
18.08.2017

Zweites Leben für gebrauchte Laborgeräte

Zweites Leben für gebrauchte Laborgeräte

Wer Laborgeräte oder eine mikrobiologische Sicherheitswerksbank benötigt, muss bei Neuanschaffungen tief in die Tasche greifen. Werden hingegen Laborgeräte nicht mehr benötigt, kostet die Entsorgung der Ausrüstung oder der Verkauf auf dem Gebrauchtwarenmarkt Zeit und Geld.

mehr >
17.08.2017

Clinerion develops data protection solution

The Basel-based startup Clinerion has filed an international patent application for its new data protection solution. The technology protects patient data within Clinerion’s Patient Recruitment System.

mehr >
15.03.2017

BaseLaunch can take full advantage of the potential of Basel's life sciences ecosystem

BaseLaunch can take full advantage of the potential of Basel's life sciences ecosystem

The new accelerator for healthcare ventures, BaseLaunch, wants to link the best start-ups to the Basel region – and in doing so, provide impulses for major players. The project will consistently focus on quality and the concentrated know-how in the region, says Managing Director Alethia de Léon.

mehr >
16.08.2017

Pratteln to get a new research site

A space for research, development and services is set to be built on the Chuenimattareal site near the Pratteln rail station. The project is being led by Bricks Group AG, and the focus will be on life sciences.

mehr >
15.08.2017

Cellestia compound enters into clinical development

Cellestia compound enters into clinical development

The Basel-based biotechnology company Cellestia has received approval for the first clinical trial on its compound CB-103. The clinical trial will be open to patients with solid tumours and haematological malignancies.

mehr >
14.03.2017

Basel impresses with quality of living

Basel impresses with quality of living

Basel is among the top ten cities with the highest quality of living in the world, according to the latest Mercer Quality of Living ranking. 2017 marks the first year that Basel was included in the ranking.

mehr >

 

(Source: http://www.baselarea.swiss/en/baselarea-swiss/channels/innovation-report.html)